uniQure (NASDAQ:QURE – Get Rating) – Research analysts at HC Wainwright lowered their Q2 2023 earnings estimates for shares of uniQure in a report released on Tuesday, May 16th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings per share of ($0.96) for the quarter, down from their prior estimate of ($0.75). HC Wainwright currently has a “Buy” rating and a $90.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($4.07) per share. HC Wainwright also issued estimates for uniQure’s Q3 2023 earnings at ($1.75) EPS, Q4 2023 earnings at ($1.75) EPS, FY2023 earnings at ($6.08) EPS, FY2024 earnings at ($3.86) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at $0.70 EPS and FY2027 earnings at $3.34 EPS.
uniQure (NASDAQ:QURE – Get Rating) last announced its quarterly earnings data on Monday, February 27th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.89) by $1.04. The company had revenue of $102.75 million during the quarter, compared to analyst estimates of $55.37 million. uniQure had a negative net margin of 143.01% and a negative return on equity of 35.03%.
uniQure Price Performance
Shares of QURE stock opened at $20.72 on Thursday. The firm has a market cap of $985.86 million, a P/E ratio of -6.20 and a beta of 1.18. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.67 and a quick ratio of 6.56. uniQure has a 1-year low of $12.83 and a 1-year high of $28.25. The firm has a fifty day moving average of $19.99 and a two-hundred day moving average of $21.37.
Insider Transactions at uniQure
In related news, CEO Matthew C. Kapusta sold 2,521 shares of the business’s stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $21.39, for a total transaction of $53,924.19. Following the transaction, the chief executive officer now directly owns 468,743 shares of the company’s stock, valued at $10,026,412.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 5,919 shares of company stock valued at $126,208 over the last ninety days. Corporate insiders own 3.10% of the company’s stock.
Hedge Funds Weigh In On uniQure
Several large investors have recently bought and sold shares of QURE. Arizona State Retirement System increased its holdings in uniQure by 4.0% in the 4th quarter. Arizona State Retirement System now owns 11,867 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 458 shares during the period. Comerica Bank raised its position in shares of uniQure by 2.1% in the 3rd quarter. Comerica Bank now owns 29,731 shares of the biotechnology company’s stock valued at $549,000 after acquiring an additional 620 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of uniQure by 6.6% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,749 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 792 shares during the period. Exchange Traded Concepts LLC raised its holdings in uniQure by 3.4% during the 4th quarter. Exchange Traded Concepts LLC now owns 30,481 shares of the biotechnology company’s stock worth $691,000 after buying an additional 1,016 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in uniQure by 152.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,231 shares during the period. 88.03% of the stock is currently owned by institutional investors and hedge funds.
uniQure Company Profile
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
- Get a free copy of the StockNews.com research report on uniQure (QURE)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.